Literature DB >> 34956848

The impact of changing the diagnostic algorithm for TB in Manicaland, Zimbabwe.

K Zvinoera1, I D Olaru2,3, P Khan2, J Mutsvangwa3, C M Denkinger4,5, V Kampira1, D Coutinho1, H Mutunzi6, M Pepukai3, E Chikaka7, S Zinyowera8, S Mharakurwa7, K Kranzer2,3,9.   

Abstract

SETTING: Governmental health facilities performing TB diagnostics in Manicaland, Zimbabwe.
OBJECTIVE: To investigate the effect of making Xpert® MTB/RIF the primary TB diagnostic for all patients presenting with presumptive TB on 1) the number of samples investigated for TB, 2) the proportion testing TB-positive, and 3) the proportion of unsuccessful results over time.
DESIGN: This retrospective study used data from GeneX-pert downloads, laboratory registers and quality assurance reports between 1 January 2017 and 31 December 2018.
RESULTS: The total number of Xpert tests performed in Manicaland increased from 3,967 in the first quarter of 2017 to 7,011 in the last quarter of 2018. Mycobacterium tuberculosis DNA was detected in 4.9-8.6% of the samples investigated using Xpert, with a higher yield in 2017 than in 2018. The overall proportion of unsuccessful Xpert assays due to "no results", errors and invalid results was 6.3%, and highly variable across sites.
CONCLUSION: Roll out of more sensitive TB diagnostics does not necessarily result in an increase of microbiologically confirmed TB diagnosis. While the number of samples tested using Xpert increased, the proportion of TB-positive tests decreased. GeneXpert soft- and hardware infrastructure needs to be strengthened to reduce the rate of unsuccessful assays and therefore, costs and staff time.
© 2021 The Union.

Entities:  

Keywords:  Xpert MTB/Rif; Zimbabwe; diagnostics; tuberculosis

Year:  2021        PMID: 34956848      PMCID: PMC8680185          DOI: 10.5588/pha.21.0040

Source DB:  PubMed          Journal:  Public Health Action        ISSN: 2220-8372


  9 in total

1.  Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2019-06-07

2.  Has the utilisation of Xpert® MTB/RIF in Manicaland Province, Zimbabwe, improved with new guidance on whom to test?

Authors:  A Jokwiro; C Timire; A D Harries; P T Gwinji; A Mulema; K C Takarinda; P T Mafaune; C Sandy
Journal:  Public Health Action       Date:  2018-09-21

3.  Access to second-line drug susceptibility testing results among patients with Rifampicin resistant tuberculosis after introduction of the Hain® Line Probe Assay in Southern provinces, Zimbabwe.

Authors:  Collins Timire; Charles Sandy; Ajay M V Kumar; Mkhokheli Ngwenya; Barbara Murwira; Kudakwashe C Takarinda; Anthony D Harries
Journal:  Int J Infect Dis       Date:  2019-02-15       Impact factor: 3.623

4.  Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries.

Authors:  Jacob Creswell; Andrew J Codlin; Emmanuel Andre; Mark A Micek; Ahmed Bedru; E Jane Carter; Rajendra-Prasad Yadav; Andrei Mosneaga; Bishwa Rai; Sayera Banu; Miranda Brouwer; Lucie Blok; Suvanand Sahu; Lucica Ditiu
Journal:  BMC Infect Dis       Date:  2014-01-02       Impact factor: 3.090

5.  The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis.

Authors:  Lucia Cilloni; Han Fu; Juan F Vesga; David Dowdy; Carel Pretorius; Sevim Ahmedov; Sreenivas A Nair; Andrei Mosneaga; Enos Masini; Suvanand Sahu; Nimalan Arinaminpathy
Journal:  EClinicalMedicine       Date:  2020-10-24

6.  Understanding the incremental value of novel diagnostic tests for tuberculosis.

Authors:  Nimalan Arinaminpathy; David Dowdy
Journal:  Nature       Date:  2015-12-03       Impact factor: 49.962

7.  Implementing the Xpert® MTB/RIF Diagnostic Test for Tuberculosis and Rifampicin Resistance: Outcomes and Lessons Learned in 18 Countries.

Authors:  Elisa Ardizzoni; Emmanuel Fajardo; Peter Saranchuk; Martina Casenghi; Anne-Laure Page; Francis Varaine; Cara S Kosack; Pamela Hepple
Journal:  PLoS One       Date:  2015-12-15       Impact factor: 3.240

8.  Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study.

Authors:  Alexandra B Hogan; Britta L Jewell; Ellie Sherrard-Smith; Juan F Vesga; Oliver J Watson; Charles Whittaker; Arran Hamlet; Jennifer A Smith; Peter Winskill; Robert Verity; Marc Baguelin; John A Lees; Lilith K Whittles; Kylie E C Ainslie; Samir Bhatt; Adhiratha Boonyasiri; Nicholas F Brazeau; Lorenzo Cattarino; Laura V Cooper; Helen Coupland; Gina Cuomo-Dannenburg; Amy Dighe; Bimandra A Djaafara; Christl A Donnelly; Jeff W Eaton; Sabine L van Elsland; Richard G FitzJohn; Han Fu; Katy A M Gaythorpe; William Green; David J Haw; Sarah Hayes; Wes Hinsley; Natsuko Imai; Daniel J Laydon; Tara D Mangal; Thomas A Mellan; Swapnil Mishra; Gemma Nedjati-Gilani; Kris V Parag; Hayley A Thompson; H Juliette T Unwin; Michaela A C Vollmer; Caroline E Walters; Haowei Wang; Yuanrong Wang; Xiaoyue Xi; Neil M Ferguson; Lucy C Okell; Thomas S Churcher; Nimalan Arinaminpathy; Azra C Ghani; Patrick G T Walker; Timothy B Hallett
Journal:  Lancet Glob Health       Date:  2020-07-13       Impact factor: 26.763

Review 9.  Lockdown measures in response to COVID-19 in nine sub-Saharan African countries.

Authors:  Najmul Haider; Abdinasir Yusuf Osman; Audrey Gadzekpo; George O Akipede; Danny Asogun; Rashid Ansumana; Richard John Lessells; Palwasha Khan; Muzamil Mahdi Abdel Hamid; Dorothy Yeboah-Manu; Leonard Mboera; Elizabeth Henry Shayo; Blandina T Mmbaga; Mark Urassa; David Musoke; Nathan Kapata; Rashida Abbas Ferrand; Pascalina-Chanda Kapata; Florian Stigler; Thomas Czypionka; Alimuddin Zumla; Richard Kock; David McCoy
Journal:  BMJ Glob Health       Date:  2020-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.